Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model.

ABSTRACT:

Background

Recent evidence links aberrant activation of Hedgehog (Hh) signaling with the pathogenesis of several cancers including medulloblastoma, basal cell, small cell lung, pancreatic, prostate and ovarian. This investigation was designed to determine if inhibition of this pathway could inhibit serous ovarian cancer growth.

Methodology

We utilized an in vivo pre-clinical model of serous ovarian cancer to characterize the anti-tumor activity of Hh pathway inhibitors cyclopamine and a clinically applicable derivative, IPI-926. Primary human serous ovarian tumor tissue was used to generate tumor xenografts in mice that were subsequently treated with cyclopamine or IPI-926.

Principal findings

Both compounds demonstrated significant anti-tumor activity as single agents

SUBMITTER: McCann CK 

PROVIDER: S-EPMC3226669 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature